NSCLC is a molecularly heterogeneous disease, and the most common molecular drivers include activating mutations in EGFR, KRAS, and BRAF, as well as gene rearrangements involving ALK, ROS1, and RET, which promote uncontrolled cell growth and survival. This evidence concerns the gene KRAS and non-small cell lung carcinoma.